{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:23:14Z","timestamp":1789899794985,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.antiviral.2019.05.009","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T01:00:53Z","timestamp":1558746053000},"page":"68-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors"],"prefix":"10.1016","volume":"168","author":[{"given":"R.","family":"Farrukee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7971-9904","authenticated-orcid":false,"given":"J.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-5308","authenticated-orcid":false,"given":"P.C.","family":"Reading","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.05.009_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/135965350601100804","article-title":"Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds","volume":"11","author":"Abed","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.05.009_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1371\/journal.ppat.1002431","article-title":"Role of permissive neuraminidase mutations in influenza A\/Brisbane\/59\/2007-like (H1N1) viruses","volume":"7","author":"Abed","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.05.009_bib3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/JVI.02681-13","article-title":"Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets","volume":"88","author":"Abed","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1006\/viro.1999.0058","article-title":"In vitro selection and characterisation of influenza B\/Beijing\/1\/87 isolates with altered susceptibility to zanamivir","volume":"265","author":"Barnett","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.05.009_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1086\/650464","article-title":"Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses","volume":"201","author":"Baz","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.05.009_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/viro.1998.9194","article-title":"The Interaction of Neuraminidase and Hemagglutinin Mutations in Influenza Virus in Resistance to 4-Guanidino-Neu5Ac2en","volume":"246","author":"Blick","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.05.009_bib7","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/molbev\/msu173","article-title":"An experimentally determined evolutionary model dramatically improves phylogenetic fit","volume":"31","author":"Bloom","year":"2014","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.05.009_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022201","article-title":"A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase","volume":"6","author":"Bloom","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.05.009_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.virusres.2008.01.014","article-title":"Identification of amino acids in the HA of H3 influenza viruses that determine infectivity levels in primary swine respiratory epithelial cells","volume":"133","author":"Busch","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2019.05.009_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004065","article-title":"Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses","volume":"10","author":"Butler","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.05.009_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3851\/IMP2672","article-title":"Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir","volume":"23","author":"Cao","year":"2014","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2019.05.009_bib13","first-page":"366","article-title":"Emergence of avian influenza A(H7N9) virus causing severe human illness - China, February-April 2013","volume":"62","author":"CDC","year":"2013","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.antiviral.2019.05.009_bib14","author":"ChinaBioToday"},{"key":"10.1016\/j.antiviral.2019.05.009_bib15","article-title":"Adamantane-resistant influenza a viruses in the world (1902\u20132013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.05.009_bib16","series-title":"Epidemiological and Genetic Characteristics of the Fifth Avian Influenza A(H7N9) Wave in Suzhou, China, from October 2016 to April 2017. Virus Genes","author":"Dong","year":"2018"},{"key":"10.1016\/j.antiviral.2019.05.009_bib17","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/jac\/dkv065","article-title":"Influenza viruses with B\/Yamagata- and B\/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility","volume":"70","author":"Farrukee","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2019.05.009_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01081-18","article-title":"Characterization of influenza B virus variants with reduced neuraminidase inhibitor susceptibility","volume":"62","author":"Farrukee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.05.009_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2007.10.020","article-title":"Mutations of neuraminidase implicated in neuraminidase inhibitors resistance","volume":"41","author":"Ferraris","year":"2008","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.virol.2005.08.035","article-title":"Evolution of the receptor binding phenotype of influenza A (H5) viruses","volume":"344","author":"Gambaryan","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.05.009_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1305584","article-title":"Clinical findings in 111 cases of influenza A (H7N9) virus infection","volume":"368","author":"Gao","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.05.009_bib22","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1305584","article-title":"Clinical findings in 111 cases of influenza A (H7N9) virus infection","volume":"368","author":"Gao","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.05.009_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.virusres.2004.02.034","article-title":"Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors","volume":"103","author":"Gubareva","year":"2004","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2019.05.009_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2017.08.004","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015\u20132016","volume":"146","author":"Gubareva","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.05.009_bib25","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1128\/JVI.70.3.1818-1827.1996","article-title":"Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en","volume":"70","author":"Gubareva","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib26","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1086\/314440","article-title":"Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus","volume":"178","author":"Gubareva","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.05.009_bib27","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1128\/JVI.71.5.3385-3390.1997","article-title":"Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en","volume":"71","author":"Gubareva","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib28","doi-asserted-by":"crossref","first-page":"S566","DOI":"10.1093\/infdis\/jiw625","article-title":"Drug susceptibility evaluation of an influenza A(H7N9) virus by analyzing recombinant neuraminidase proteins","volume":"216","author":"Gubareva","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.05.009_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3854","article-title":"Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility","volume":"4","author":"Hai","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2019.05.009_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1183\/09031936.00006414","article-title":"Severe influenza A H7N9 pneumonia with rapid virological response to intravenous zanamivir","volume":"44","author":"Ho","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.antiviral.2019.05.009_bib31","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1073\/pnas.100133697","article-title":"A DNA transfection system for generation of influenza A virus from eight plasmids","volume":"97","author":"Hoffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2019.05.009_bib32","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s007050170002","article-title":"Universal primer set for the full-length amplification of all influenza A viruses","volume":"146","author":"Hoffmann","year":"2001","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib33","series-title":"Association between Adverse Clinical Outcome in Human Disease Caused by Novel Influenza A H7N9 Virus and Sustained Viral Shedding and Emergence of Antiviral Resistance. Lancet (London, England)","first-page":"381","author":"Hu","year":"2013"},{"key":"10.1016\/j.antiviral.2019.05.009_bib34","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(13)61125-3","article-title":"Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance","volume":"381","author":"Hu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.05.009_bib35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2016.06.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015","volume":"132","author":"Hurt","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.05.009_bib36","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1128\/JVI.00373-10","article-title":"Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model","volume":"84","author":"Hurt","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-61779-621-0_7","article-title":"The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors","volume":"865","author":"Hurt","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.chom.2017.09.008","article-title":"A highly pathogenic avian H7N9 influenza virus isolated from A human is lethal in some ferrets infected via respiratory droplets","volume":"22","author":"Imai","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.05.009_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2017.1333907","article-title":"Tackling a novel lethal virus: a focus on H7N9 vaccine development","volume":"16","author":"Isakova-Sivak","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2019.05.009_bib40","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"418","author":"Itzstein","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.05.009_bib41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.15585\/mmwr.mm6609e2","article-title":"Increase in human infections with avian influenza A(H7N9) virus during the fifth epidemic \u2014 China, october 2016\u2013february 2017","volume":"66","author":"Iuliano","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.antiviral.2019.05.009_bib42","doi-asserted-by":"crossref","first-page":"12911","DOI":"10.1128\/JVI.01522-07","article-title":"Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies","volume":"81","author":"Kaverin","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/JVI.78.1.240-249.2004","article-title":"Structural differences among hemagglutinins of influenza a virus subtypes are reflected in their antigenic architecture: analysis of H9 escape mutants","volume":"78","author":"Kaverin","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib44","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3201\/eid2308.170600","article-title":"Human infection with highly pathogenic avian influenza A(H7N9) virus, China","volume":"23","author":"Ke","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.05.009_bib45","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/infdis\/jix296","article-title":"Emergence of oseltamivir-resistant H7N9 influenza viruses in immunosuppressed cynomolgus macaques","volume":"216","author":"Kiso","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"20","key":"10.1016\/j.antiviral.2019.05.009_bib46","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1001\/jama.2013.6086","article-title":"CDC: use antivirals early, aggressively for H7N9 flu","volume":"309","author":"Kuehn","year":"2013","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2019.05.009_bib47","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1304617","article-title":"Epidemiology of human infections with avian influenza A(H7N9) virus in China","volume":"370","author":"Li","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.05.009_bib48","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1304617","article-title":"Epidemiology of human infections with avian influenza A(H7N9) virus in China","volume":"370","author":"Li","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.05.009_bib49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/cid\/cit638","article-title":"Virological, serological, and antiviral studies in an imported human case of avian influenza A(H7N9) virus in Taiwan","volume":"58","author":"Lin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.05.009_bib50","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1128\/JVI.03513-14","article-title":"Neuraminidase mutations conferring resistance to oseltamivir in influenza A(H7N9) viruses","volume":"89","author":"Marjuki","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu447","article-title":"Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan","volume":"211","author":"Marjuki","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.05.009_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/AAC.40.1.40","article-title":"Generation and characterization of variants of NWS\/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en","volume":"40","author":"McKimm-Breschkin","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.05.009_bib53","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1128\/JVI.72.3.2456-2462.1998","article-title":"Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors","volume":"72","author":"McKimm-Breschkin","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013","volume":"110","author":"Meijer","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.05.009_bib55","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1128\/JVI.76.11.5380-5386.2002","article-title":"In vitro selection and characterization of influenza a (a\/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675","volume":"76","author":"Molla","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib56","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/AAC.01773-10","article-title":"Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus","volume":"55","author":"Naughtin","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.05.009_bib57","doi-asserted-by":"crossref","first-page":"10891","DOI":"10.1128\/JVI.01514-15","article-title":"Unique determinants of neuraminidase inhibitor resistance among N3, N7, and N9 avian influenza viruses","volume":"89","author":"Song","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.05.009_bib58","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1128\/AAC.42.12.3234","article-title":"Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071","volume":"42","author":"Tai","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.05.009_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2015.02.003","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014","volume":"117","author":"Takashita","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.05.009_bib60","first-page":"017","article-title":"Epidemiological, clinical, and virologic features of two family clusters of avian influenza A (H7N9) virus infections in Southeast China","volume":"7","author":"Xie","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.05.009_bib61","article-title":"Clinical, virological and immunological features from patients infected with Re-emergent avian-origin human H7N9 influenza disease of varying severity in guangdong province","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.05.009_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00396-13","article-title":"Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R\/K viral population","volume":"4","author":"Yen","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2019.05.009_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40506-016-0085-5","article-title":"Japanese surveillance systems and treatment for influenza","volume":"8","author":"Zaraket","year":"2016","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.05.009_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/emi.2014.80","article-title":"Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution","volume":"3","author":"Zhang","year":"2014","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.antiviral.2019.05.009_bib65","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/ijerph120100816","article-title":"Cluster of human infections with avian influenza a (H7N9) cases: a temporal and spatial analysis","volume":"12","author":"Zhang","year":"2015","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.antiviral.2019.05.009_bib66","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5365\/wpsar.2017.8.1.001","article-title":"Sudden increase in human infection with avian influenza A(H7N9) virus in China, September-December 2016","volume":"8","author":"Zhou","year":"2017","journal-title":"Western Pac Surveill Response J"},{"key":"10.1016\/j.antiviral.2019.05.009_bib67","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3201\/eid2308.170640","article-title":"Preliminary epidemiology of human infections with highly pathogenic avian influenza A(H7N9) virus, China, 2017","volume":"23","author":"Zhou","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.05.009_bib68","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.2807\/1560-7917.ES.2017.22.19.30533","article-title":"Biological characterisation of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in humans, in mainland China, 2016 to 2017","volume":"22","author":"Zhu","year":"2017","journal-title":"Euro Surveill."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T16:44:53Z","timestamp":1663519493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218306739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":68,"alternative-id":["S0166354218306739"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.05.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}